Research Tracker›Biomarker Atlas›Long COVID›Asymmetric dimethylarginine (ADMA)

Asymmetric dimethylarginine (ADMA) in Long COVID

In Long COVID (PASC, Post-Acute Sequelae of COVID-19), published studies report higher levels of Asymmetric dimethylarginine (ADMA), also described as NO synthase inhibitor, than in healthy controls. Symptom domains tied to this marker in the source include reduced NO bioavailability. The finding is drawn from Thomas et al. 2024; it describes group-level differences, not a threshold that classifies an individual.

↑ ElevatedVascularLOINC 10988-1

Summary

Direction in Long COVID↑ Elevated — higher than in the comparison group
CategoryVascular
Also described asNO synthase inhibitor
Compared againstHC (healthy controls)
Associated symptomsReduced NO bioavailability
Test typeBlood test (serum / plasma / whole blood)
LOINC code10988-1
SourceThomas et al. 2024 — doi:10.1007/s40291-024-00731-z
Condition atlasLong COVID Biomarker Atlas

Trials, interventions and tests

Commercial test availability

Asymmetric dimethylarginine (ADMA) — specialty laboratory test.

Links are for reference only; availability, specimen requirements and coverage vary by location.

Related Vascular markers in Long COVID

Full list: Long COVID Biomarker Atlas.

Frequently asked questions

Is Asymmetric dimethylarginine (ADMA) high or low in Long COVID?

Elevated. Studies summarised in the OSMF atlas report higher Asymmetric dimethylarginine (ADMA) in Long COVID than in healthy controls. Source: Thomas et al. 2024.

What symptoms is Asymmetric dimethylarginine (ADMA) associated with in Long COVID?

The cited literature associates this marker with Reduced NO bioavailability. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Asymmetric dimethylarginine (ADMA)?

It is measured as a blood test (serum / plasma / whole blood). The standard laboratory code is LOINC 10988-1. Commercial laboratories such as Quest Diagnostics, LabCorp list an orderable assay.

Is one abnormal Asymmetric dimethylarginine (ADMA) result diagnostic of Long COVID?

No. No single biomarker is diagnostic of Long COVID. Asymmetric dimethylarginine (ADMA) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Cite this page

Open Source Medicine Foundation. (2026). Asymmetric dimethylarginine (ADMA) in Long COVID: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/long-covid/asymmetric-dimethylarginine-adma.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-06-29 · Page generated from long-covid.json · Browse: Long COVID atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.